|Genomics & Big Data Summit|
Metabolomics - Advances & Applications in Human Disease
Next Generation Sequencing
Big Data Bioinformatics
CRISPR & Genome Engineering
We invite you to attend the Next Generation Sequencing Conference, which is part of The Genomics & Big Data Summit and takes place in September 26-27, 2017.
Next generation sequencing has made it possible to obtain genetic information from biological systems by rapid and inexpensive methods. Therefore, the ability to analyze genomes and protein interactions has been accomplished. Now, the branches of next generation sequencing has expanded to single cell analyses, RNA sequencing approaches, and discoveries in the microbiome space. The race for faster, cheaper, and higher precision sequencing approaches has been a constant goal for researchers so that there are improved methods in this field.
This meeting will provide attendees with a better understanding of developments in new next generation sequencing technologies alongside clinical applications. There will be a focus on medical sequencing for patient characterization in targeted therapies through vast methods like single cell and RNA sequencing. Implications for how diseases should be treated will be discussed through the examination of data produced from reputable assays.
Joint Plenary Sessions:
- Opening Keynote Session – Historical Perspective & Current State of the Industry
- Round Table Discussions
- Lunch Session – Ethical Challenges of Big Data and Genomics Application
- Award Ceremony & Closing Keynote Session – Predictions for the Future
Next Generation Sequencing:
- RNA and DNA Sequencing including Single Cell Analysis
- Clinical Diagnostic Sequencing and Emerging Technologies
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.